INTENDED CHANGE IN PC TREATMENT!
Efficacy endpoints included: detection rate (DR), correct detection rate (CDR). The number of lesions detected, their size and the intended change in PC treatment due to the 64Cu-SAR-bisPSMA results were recorded.
Using histopathology as the source of truth (which it is), we find that 64Cu-Sar-bisPSMA performs even better than what we previously knew, when compared to SOC (Pylarify and Illucix or their equivalents). This is confirmatory. Nice!
In simple terms, 24 out of 50 patients are getting what doctors consider to be inappropriate treatment recommendations, not because of bad doctors, but because we are stuck with Pylarify and Illuccix as our best tools in the kit!
Treating cancer might be considered the fun part (67Cu-sar-bisPSMA superiority to SOC), but it starts with getting the right diagnosis!
Lets let that sink, folks! The future is bright!
Looking forward to the rest of the diagnostics in development:
1. 64Cu-SARTATE: Targets Neuroendocrine Tumors (NETs) and Neuroblastoma, focusing on somatostatin receptor-positive imaging.
2. 64Cu-sar-BOMBESIN: Pan-cancer imaging for Prostate, Breast, and other cancers with gastrin-releasing peptide receptor (GRPR) overexpression.
3. 64Cu-sar-FAPI: Pan-cancer imaging for Breast, Colon, and other cancers involving fibroblast activation protein (FAP)-rich tumor stroma.
4. 64Cu-Tz-SarAr: Pre-targeted imaging for pan-cancer, including Pancreatic Cancer, using TCO–tetrazine click chemistry for high precision.
(20min delay)